- Home
- / CRISPR Therapeutics
CRISPR Therapeutics
Stock Price
$48.9
2024-10-29
Market Capitalization
$4.2 B
2024-10-29
Revenue
$3.5 M
FY, 2025
CRISPR Therapeutics Summary
Company Summary
- Overview
- CRISPR Therapeutics is a gene editing company focused on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform.
- Type
- Public
- Status
- Active
- Founded
- 2013
- HQ
- Zug, CH | view all locations
- Website
- http://crisprtx.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Shaun Foy, Co-Founder
Stephen Kennedy, Head of Technical Operations
Daniel Anderson, Scientific Founder and Advisory Board Member
LocationsView all
4 locations detected
Zug, ZG HQ
Switzerland
Baarerstrasse 14/V8
Cambridge, MA
United States
610 Main St
San Francisco, CA
United States
455 Mission Bay Boulevard South, San Francisco
Greater London, England
United Kingdom
85 Tottenham Court Rd
CRISPR Therapeutics Financials
Summary Financials
- Revenue (Q1, 2026)
- $1.5M
- Net income (Q1, 2026)
- ($122.9M)
- Cash (Q1, 2026)
- $423.3M
- EBIT (Q1, 2026)
- ($130.2M)
- Enterprise value
- $4.5B